Price
No data yet.
Social Signal Score
70
5d
70
1 mentions
—
30d
70
1 mentions
—
60d
70
1 mentions
—
90d
70
1 mentions
—
news: 1
Revenue
$16.27B+843.28%Jun 2006Dec 2025
Analyst Estimates
FY2025
$12.34
$12.08–$13.03
1 analysts
FY2026
$7.47-39% YoY
$7.32–$7.89
1 analysts
FY2027
$12.30+65% YoY
$12.04–$13.00
1 analysts
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen Bradley Saad
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 9,557
- Beta
- 0.40
- Country
- ZA
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.11
Financials
Revenue
$16.27B+843.3%Net Income
$1.40B+339.5%EBITDA
$3.87B+699.4%Free Cash Flow
$2.33B+4801.4%EPS (diluted)
$3.15+266.3%Shares Outstanding (diluted)
444.60M+20.2%Operating Expenses
$4.14BR&DSG&A
Cash & Debt
$5.61BCash & investmentsTotal debt
Return of Capital
$896.39MBuybacksDividends
Dividend per Share
$0.12Quote
Day Range
$8.49 – $9.22
52-Week Range
$5.24 – $9.45
Volume
$1.1K
Market Cap
$4.09B
50-Day Avg
$9.07
200-Day Avg
$7.86
Prev Close
$8.80
Open
$8.49
Valuation & Ratios
P/E Ratio
-49.19
EPS
$-2.44
P/B Ratio
0.63
P/S Ratio
1.23
Debt/Equity
0.43
Current Ratio
2.21
Dividend Yield
+3.0%
Gross Margin
+44.1%
Returns & Efficiency
Return on Equity
-1.3%
Return on Assets
-0.8%
FCF Yield
+0.2%
EV/EBITDA
38.42
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $43.36B | $-1.08B | $-2.44 |
| 2024 | $44.71B | $4.40B | $9.91 |
| 2023 | $40.71B | $5.23B | $11.77 |
| 2022 | $38.61B | $6.49B | $14.32 |
| 2021 | $37.77B | $4.81B | $10.53 |
| 2020 | $38.65B | $4.66B | $10.64 |
| 2019 | $38.87B | $6.46B | $14.16 |
| 2018 | $42.60B | $6.01B | $13.17 |
| 2017 | $41.20B | $5.10B | $11.17 |
| 2016 | $35.60B | $4.30B | $9.45 |
| 2015 | $36.13B | $5.20B | $11.40 |
| 2014 | $29.52B | $5.01B | $10.98 |
| 2013 | $19.31B | $3.52B | $7.73 |
| 2012 | $15.26B | $2.82B | $6.46 |
Valuation
APNHYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Sep 3Sep 3
Social Signal Score
70
5d
70
1 mentions
—
30d
70
1 mentions
—
60d
70
1 mentions
—
90d
70
1 mentions
—
news: 1
Mentions (1)
- Newsseekingalpha.com·6h ago·Positive
Aspen Pharmacare Holdings Limited (APNHY) Q4 2026 Earnings Call Transcript Aspen Pharmacare Holdings Limited (APNHY) Q4 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Sep 3(date passed)
1of 2 quarters beat consensus
Typical surprise -8.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Sep 3$0.57 vs $0.57beat
- Wed, Aug 30$0.39 vs $0.48miss
Estimates and results for APNHY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.